These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 2175793)

  • 1. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.
    Adams JU; Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1027-32. PubMed ID: 2175793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
    Mjanger E; Yaksh TL
    J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox.
    Barrett AC; Smith ES; Picker MJ
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1061-70. PubMed ID: 12649297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
    Zimmerman DM; Leander JD; Reel JK; Hynes MD
    J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
    Takemori AE; Portoghese PS
    J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence.
    Holtzman SG
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1033-41. PubMed ID: 12604679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats.
    Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1992 Jul; 262(1):1-9. PubMed ID: 1625189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of morphine-like discriminative effects by beta-funaltrexamine.
    Holtzman SG
    Pharmacol Biochem Behav; 1997 Aug; 57(4):771-7. PubMed ID: 9259005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clocinnamox: a novel, systemically-active, irreversible opioid antagonist.
    Comer SD; Burke TF; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1051-6. PubMed ID: 1326622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
    Liu-Chen LY; Yang HH; Li S; Adams JU
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
    Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
    Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral effects of opioid peptides selective for mu or delta receptors. I. Morphine-like discriminative stimulus effects.
    Locke KW; Holtzman SG
    J Pharmacol Exp Ther; 1986 Sep; 238(3):990-6. PubMed ID: 3018230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased analgesic potency of mu agonists after continuous naloxone infusion in rats.
    Paronis CA; Holtzman SG
    J Pharmacol Exp Ther; 1991 Nov; 259(2):582-9. PubMed ID: 1658305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracranial self-stimulation in rats: sensitization to an opioid antagonist following acute or chronic treatment with mu opioid agonists.
    Easterling KW; Holtzman SG
    J Pharmacol Exp Ther; 1997 Apr; 281(1):188-99. PubMed ID: 9103497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of mu- and delta-selective opioid agonists in the guinea pig ileum preparation: differentiation into peptide and nonpeptide classes with beta-funaltrexamine.
    Ward SJ; LoPresti D; James DW
    J Pharmacol Exp Ther; 1986 Aug; 238(2):625-31. PubMed ID: 3016244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
    Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.
    Jiang Q; Seyed-Mozaffari A; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1995 May; 273(2):680-8. PubMed ID: 7752070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.